E25Bio

Founders & Leadership

Prashant Chouta, Irene Bosch, Bobby Brooke Herrera, Lee Gehrke

Background

MIT Institute for Medical Engineering & Science, MIT Tata Center

Industry

Biotech & Life Sciences

Rapid, accurate diagnosis of infectious disease at the point of care.

The idea for E25Bio was simple, cut through the inefficient infrastructure and bureaucracies that did little to impede epidemics of dengue, chikungunya, and Zika. The company has developed a rapid, at-home fever panel that detects deadly mosquito-borne illnesses in minutes, not days. It is a simple, over-the-counter blood test that will help diagnose these diseases in time to receive potentially life-saving treatment. This test empowers the patient, giving them control of their healthcare and helping avoid arduous diagnosis processes.

Take the typical detection process for dengue, chikungunya, and Zika, for example. After an initial hospital or clinic visit, the patient consults with a doctor, then has his or her blood drawn. A lab workup is performed and test results are assessed. It’s an exercise that takes days at the minimum, and in many instances, is measured in weeks. Such delays elevate the risk of patient fatality by 20%. The story is similar for mosquito-borne illnesses across the globe.

For CEO Prashant Chouta, E25Bio is about detecting diseases, preventing future pandemics, and saving lives. The test, which works with whole blood from a simple finger prick, is the first of its kind to screen for active virus, making it more effective than a traditional blood draw. It is also sold over-the-counter and produces results within a few minutes. The technology was developed in MIT’s Gehrke lab with ongoing work now led by CSO Bobby Brooke Herrera. This convenience, accuracy, and inherent affordability is the result of what E25Bio calls an “obsessed, scrappy team, wanting to do something that is, above all, novel and creative.”

E25Bio is putting a specialized central medical testing facility within a single over-the-counter test. Such consolidation subverts the disparity of access to life-changing medical knowledge. And the company’s unique ability to quickly produce effective antibody pairs means that its test has the potential to help patients across the globe. Disease, after all, knows no borders.

Get in touch

Are you a founder?
We are always looking for new talent in the Tough Tech world.

Apply